Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021
|
| _version_ | 1797108043045928960 |
|---|---|
| author | Wellens, J Edmans, M Obolski, U McGregor, CGC Simmonds, P Turner, M Jarvis, L Skelly, D Dunachie, S Barnes, E Eyre, DW Colombel, J-F Wong, S-Y Klenerman, P Lindsay, JO Satsangi, J Thompson, CP |
| author_facet | Wellens, J Edmans, M Obolski, U McGregor, CGC Simmonds, P Turner, M Jarvis, L Skelly, D Dunachie, S Barnes, E Eyre, DW Colombel, J-F Wong, S-Y Klenerman, P Lindsay, JO Satsangi, J Thompson, CP |
| author_sort | Wellens, J |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T07:22:29Z |
| format | Journal article |
| id | oxford-uuid:2bb50e28-43af-4a15-88b0-567b46ae4fae |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:22:29Z |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:2bb50e28-43af-4a15-88b0-567b46ae4fae2022-11-04T11:16:29ZCombination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel diseaseJournal articlehttp://purl.org/coar/resource_type/c_545buuid:2bb50e28-43af-4a15-88b0-567b46ae4faeEnglishSymplectic ElementsBMJ Publishing Group2021Wellens, JEdmans, MObolski, UMcGregor, CGCSimmonds, PTurner, MJarvis, LSkelly, DDunachie, SBarnes, EEyre, DWColombel, J-FWong, S-YKlenerman, PLindsay, JOSatsangi, JThompson, CP |
| spellingShingle | Wellens, J Edmans, M Obolski, U McGregor, CGC Simmonds, P Turner, M Jarvis, L Skelly, D Dunachie, S Barnes, E Eyre, DW Colombel, J-F Wong, S-Y Klenerman, P Lindsay, JO Satsangi, J Thompson, CP Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title | Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title_full | Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title_fullStr | Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title_full_unstemmed | Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title_short | Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease |
| title_sort | combination therapy of infliximab and thiopurines but not monotherapy with infliximab or vedolizumab is associated with attenuated iga and neutralisation responses to sars cov 2 in inflammatory bowel disease |
| work_keys_str_mv | AT wellensj combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT edmansm combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT obolskiu combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT mcgregorcgc combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT simmondsp combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT turnerm combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT jarvisl combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT skellyd combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT dunachies combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT barnese combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT eyredw combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT colombeljf combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT wongsy combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT klenermanp combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT lindsayjo combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT satsangij combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease AT thompsoncp combinationtherapyofinfliximabandthiopurinesbutnotmonotherapywithinfliximaborvedolizumabisassociatedwithattenuatedigaandneutralisationresponsestosarscov2ininflammatoryboweldisease |